display
Moscow (dpa) - The Russian pharmaceutical company R-Pharm plans to produce the Sputnik V corona vaccine developed in Moscow from June or July in Illertissen, Bavaria.
"We are making every effort so that it can start in the summer," said R-Pharm manager Alexander Bykov of the German press agency in Moscow.
Millions of cans could be produced every month in Illertissen.
"We already have the equipment and the cadres there," said Bykov.
He did not give the exact production capacity.
The European Medicines Agency (EMA) is currently examining the approval of the preparation.
"We are waiting for the decision of the EMA because that is a legitimate basis on which we can produce," said Bykov.
Other states in the EU could then also be supplied with Sputnik V from Illertissen.
The director in charge of health economics at the corporation sought trust in Russian biotechnology, which has a long history of success - for example in the development of vaccines against polio.
At an event in Moscow on German-Russian cooperation in pharmacy, EU health expert Jérôme Lepeintre said that EMA approval of the preparation was not expected until June or July.
Two EMA inspections are planned in Russia in April.
The production facilities and the storage facilities would be examined once, said the employee of the EU representation in Moscow on Tuesday evening.
display
Sputnik V was developed by the Gamaleja Research Center for Epidemiology and Microbiology in Moscow.
The vaccine has now been approved in more than 50 countries and is distributed internationally by the state direct investment fund RDIF.
© dpa-infocom, dpa: 210324-99-947403 / 2
Website Sputnik V
R-Pharm